Analysts' Top 5 Price Targets of May 27, 2025
Reading Time: 3 minutes
Liquida Technologies [US53635D2027]: Bank of America reaffirms Buy rating and raises the price target from $22 to $25 (55% upside potential) The reason for the price target increase is the approval of Yutrepia as a 505(b)(2) alternative to Tyvaso, a medication from United Therapeutics. The 505(b)(2) approval process allows for the use of existing data from a reference product, significantly reducing development costs and time. Yutrepia is very similar to Tyvaso in formulation and application, making it a direct competitor. Bank of America views...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
